Roche Products Limited

Roche Products Limited

Roche Products Limited operates as the primary UK subsidiary of the global Roche Group, a Basel-headquartered pharmaceutical and diagnostics titan controlled by the founding Hoffmann-Oeri family. The firm administers a corporate defined benefit pension scheme for its British employees, making it a captive asset owner rather than a commercial investment manager. The fund's liabilities are backed by the covenant of Roche Holding Ltd, where the pooled family voting bloc holds nearly two-thirds of equity, creating an unusually patient capital dynamic rare among UK corporate schemes. The pension fund pursues a diversified strategy across multiple asset classes, though specific allocations remain private. Its investment posture mirrors other large European corporate DB plans: a mix of liability-driven fixed income, global equities, and increasingly, private market exposures to match long-dated benefit obligations. The sponsor's operational footprint in the UK spans two Welwyn Garden City commercial properties — Hexagon Place and Broadwater Road — reinforcing the plan's physical tie to the Hertfordshire life-sciences corridor. Parent company Roche's durable cash flows from blockbuster oncology and diagnostics franchises provide a de facto backstop that most standalone UK schemes lack. The fund's governance sits within Roche's broader corporate treasury function, without a publicly named CIO or separate investment committee. Ashraf Al-Ouf, the former Managing Director of the UK subsidiary, also served on the board of Medicines Australia, reflecting the cross-border operational ties typical of a multinational sponsor. While the fund's exact size is undisclosed, UK corporate DB schemes sponsored by FTSE 100 or equivalent global parents routinely manage hundreds of millions to low billions in sterling-denominated assets, putting Roche Products Limited in the mid-tier of British occupational pension funds. No adjacent vehicles, club memberships, or external client mandates have been disclosed. The fund's structural differentiator is the asymmetry of its sponsor: a founder-controlled, research-intensive pharmaceutical group with defensive revenue streams that act as an implicit credit enhancement few peer schemes enjoy. This allows the investment committee to hold more illiquid assets through market cycles without facing the near-term funding pressure typical of UK schemes sponsored by publicly traded companies with dispersed shareholders. The scheme is a quiet but structurally privileged investor within the UK pension landscape.